J. Joseph Melenhorst, PhD
Adjunct Associate Professor of Pathology & Laboratory Medicine
Dr. Melenhorst graduated with a bachelor’s degree in continuing education from Tilburg Fontys Teacher’s College, the Netherlands, a master’s degree in Medical Biology from the Nijmegen University, the Netherlands, and a doctorate of philosophy from the Leiden University, the Netherlands. After a post-doctoral fellowship followed by a staff scientist appointment at the National Institutes of Health he was recruited to the University of Pennsylvania in 2012 by Dr. Carl June, first as Deputy Director of the Clinical Cell and Vaccine Production Facility and later as the Director of Product Development & Correlative Sciences. In this role, he was at the cusp of the first ever CAR T cell therapy approved by FDA: Kymriah. Dr. Melenhorst and his team received the National Clinical Research Achievement Award from the Clinical Research Forum in 2019, which recognizes the ten most outstanding clinical research accomplishments in the United States during the preceding twelve months.
Dr. Melenhorst is interested in understanding and improving the anti-tumor efficacy and safety of adoptively transferred chimeric antigen receptor (CAR)-modified T cells through correlative, mechanistic, and pre-clinical studies, and partly through functional genomics approaches. This includes studying human T cell biology, the tumor microenvironment, and the genetic and biological impact of lentiviral vector-mediated mutagenesis in CAR T cells from treated patients.
South Tower 9-105
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 19104-5156
Contact Jennifer Bailey